AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L

详细信息    查看全文

• 作者：Jerzy S. Pieczykolan (1)
  Konrad Kubiński (2)
  Maciej Mas?yk (2)
  Sebastian D. Pawlak (1)
  Anna Pieczykolan (1)
  Piotr K. Rózga (1)
  Micha? Szymanik (1)
  Marlena Ga??zka (1)
  Ma?gorzata Teska-Kamińska (1)
  Bart?omiej ?erek (1)
  Katarzyna Bukato (1)
  Katarzyna Poleszak (1)
  Albert Jaworski (1)
  Wojciech Stro?ek (1)
  Robert ?wider (2)
  Rafa? Zieliński (3)
  
• 关键词：TRAIL/Apo2L ; Apoptosis ; Fusion protein ; Cytotoxicity ; Cell resistance
• 刊名：Investigational New Drugs
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：32
• 期：6
• 页码：1155-1166
• 全文大小：2,593 KB
• 参考文献：1. Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27(1):19-6 CrossRef
  2. Almasan A, Ashkenazi A (2003) Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14(3-):337-48 CrossRef
  3. Ashkenazi A, Holland P, Eckhardt SG (2008) Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26(21):3621-630. doi:10.1200/JCO.2007.15.7198 CrossRef
  4. Gonzalvez F, Ashkenazi A (2010) New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29(34):4752-765. doi:10.1038/onc.2010.221 CrossRef
  5. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O’Connell M, Kelley RF, Ashkenazi A, de Vos AM (1999) Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4(4):563-71 CrossRef
  6. Bremer E (2013) Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol 2013:371854. doi:10.1155/2013/371854
  7. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schr?ter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388(6638):190-95. doi:10.1038/40657 CrossRef
  8. Fan TJ, Han LH, Cong RS, Liang J (2005) Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai) 37(11):719-27 CrossRef
  9. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D, Ashkenazi A (2005) Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 280(49):40599-0608. doi:10.1074/jbc.M509560200 CrossRef
  10. Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408(6810):377-81. doi:10.1038/35042612 CrossRef
  11. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O’Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28(17):2839-846. doi:10.1200/JCO.2009.25.1991 CrossRef
  12. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482(3):193-99 CrossRef
  13. Yu J, Wang P, Ming L, Wood MA, Zhang L (2007) SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene 26(29):4189-198. doi:10.1038/sj.onc.1210196 CrossRef
  14. McNeish IA, Bell S, McKay T, Tenev T, Marani M, Lemoine NR (2003) Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway. Exp Cell Res 286(2):186-98 CrossRef
  15. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Gschwend J
• 作者单位：Jerzy S. Pieczykolan (1)
  Konrad Kubiński (2)
  Maciej Mas?yk (2)
  Sebastian D. Pawlak (1)
  Anna Pieczykolan (1)
  Piotr K. Rózga (1)
  Micha? Szymanik (1)
  Marlena Ga??zka (1)
  Ma?gorzata Teska-Kamińska (1)
  Bart?omiej ?erek (1)
  Katarzyna Bukato (1)
  Katarzyna Poleszak (1)
  Albert Jaworski (1)
  Wojciech Stro?ek (1)
  Robert ?wider (2)
  Rafa? Zieliński (3)
  
  1. Drug Discovery Department, Adamed Group, Pieńków 149, 05-152, Czosnów, Poland
  2. Department of Molecular Biology, Institute of Biotechnology, The John Paul II Catholic University of Lublin, Konstantynów St. 1I, 20-708, Lublin, Poland
  3. Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1901 East Road, Houston, TX, 77054, USA
  
• ISSN：1573-0646

文摘